The toxicity of amyloid-beta (Aβ) is strongly associated with Alzheimer's disease (AD), which has a high incidence in the elderly worldwide. Recent evidence showed that alteration in the activity of N-methyl-Daspartate receptors (NMDARs) plays a key role in Aβ-induced neurotoxicity. However, the activation of synaptic and extrasynaptic NMDARs has distinct consequences for plasticity, gene regulation, neuronal death, and Aβ production. This review focuses on the dysregulation of synaptic and extrasynaptic NMDARs induced by Aβ. On one hand, Aβ downregulates the synaptic NMDAR response by promoting NMDAR endocytosis, leading to either neurotoxicity or neuroprotection. On the other hand, Aβ enhances the activation of extrasynaptic NMDARs by decreasing neuronal glutamate uptake and inducing glutamate spillover, subsequently causing neurotoxicity. In addition, selective enhancement of synaptic activity by low doses of NMDA, or reduction of extrasynaptic activity by memantine, a non-competitive NMDAR antagonist, halts Aβ-induced neurotoxicity. Therefore, future neuroprotective drugs for AD should aim at both the enhancement of synaptic activity and the disruption of extrasynaptic NMDAR-dependent death signaling.
Introduction
Alzheimer's disease (AD) is the most common form of dementia and is pathologically characterized by senile plaques, neurofi brillary tangles, and synaptic loss. Although the pathogenesis of the disease is still not well understood, amyloid-beta (Aβ) is widely recognized to be neurotoxic.
To date, the downstream signaling pathways of N-methyl-D-aspartate receptors (NMDARs) are thought to be involved in Aβ-induced neurotoxicity. For example, Aβ induces synaptic loss [1] [2] [3] and postsynaptic density-95 (PSD-95) degradation [4] [5] [6] , stimulates the production of reactive oxygen species (ROS) [7] [8] [9] [10] , disrupts axonal transport [11] , and causes microtubule deregulation [12] through an NMDARdependent mechanism. Furthermore, Aβ not only binds to domains within or near NMDARs in vitro and in vivo [3, 7, 9, 13] , but also directly activates NMDARs [14] [15] [16] .
NMDARs are the major subtype of ligand-gated ionotropic glutamate receptors expressed widely in the central nervous system. Based on their localization on the cell membrane, NMDARs are distinguished as synaptic or extrasynaptic. Synaptic NMDARs are classically defined as functional receptors that are activated by glutamate released during low-frequency synaptic events, whereas extrasynaptic NMDARs, which are not activated by synaptically-released glutamate from presynaptic vesicles, are found at various locations such as the cell body, the dendritic shaft, and the neck of the dendritic spine. For many years it has been thought that the degree of Ca 2+ infl ux through NMDARs is solely responsible for differences in cellular outcome: moderate levels of NMDAR activity are beneficial for neurons, while excessive activation of [17] [18] [19] [20] [21] [22] [23] . Also, selective stimulation of extrasynaptic NMDARs triggers excitotoxicity, but Ca 2+ overload through synaptic NMDARs is not neurotoxic [19, 21, 24] . This review aims to summarize recent studies on the dysregulation of synaptic and extrasynaptic NMDARs induced by Aβ, and provide new insights into the development of AD therapies based on the balance between synaptic and extrasynaptic NMDARs.
Activation of Synaptic or Extrasynaptic NMDARs

Infl uences Aβ Production
NMDAR stimulation has been reported to increase the levels of α-C-terminal fragments (C83) of amyloid precursor protein (APP) and release soluble APP (sAPP), as well as decrease the production and release of Aβ , all of which are blocked by NMDAR antagonists or α-secretase inhibitors [25] . However, chronic NMDA exposure increases the expression of neuronal Kunitz protease inhibitory domain-containing APPs (KPI-APPs; isoforms exhibiting important amyloidogenic potential), which subsequently inhibit the α-secretase candidate tumor necrosis factor-α converting enzyme, and increase the production of Aβ [26] .
To determine whether this contradiction is explainable in terms of the activation of synaptic or extrasynaptic NMDARs, they were separately activated in a series of experiments. Activation of synaptic NMDARs alone inhibits Aβ release and increases C83 production and ERK phosphorylation [25] (Fig. 1) . Aβ is produced primarily within neurons and secreted into the interstitial fl uid (ISF). Using a micro-dialysis technique to specifi cally measure dynamic changes in ISF Aβ levels in vivo, Verges et al. revealed that high doses of NMDA or NMDAR agonist activate ERK and reduce the processing of APP into Aβ, while NMDAR antagonists increase ISF Aβ levels, suggesting that basal activity of these receptors normally suppresses Aβ levels [27] . Similar to these reports, after synaptic NMDAR activation, Bordji et al. failed to detect any KPI-APPs, and Aβ levels were not modifi ed [19] . Mechanistically, stimulation of NMDARs up-regulates the genes encoding a disintegrin and metalloproteinase 10 (ADAM10), the constitutive α-secretase that governs the non-amyloidogenic pathway of APP processing, and increases the trafficking of ADAM10 to the postsynaptic membrane [28, 29] . On the other hand, selectively activating extrasynaptic NMDARs does not stimulate C83 production and ERK phosphorylation [25] , but induces a signifi cant increase in KPI-APP mRNA and Aβ production, with no change in total APP mRNA expression, implying that a shift from normal APP to KPI-APP expression causes the higher production of Aβ [19] (Fig. 1 ).
Dysregulation of Synaptic NMDARs Induced by
Aβ
Aβ Promotes Synaptic NMDAR Endocytosis
To determine the effect of Aβ on cell surface (both synaptic and extrasynaptic) NMDAR expression, Snyder et al.
treated cultured cortical neurons with Aβ for 1 h and found that Aβ reduces the surface expression of the NR2B and NR1 subunits of NMDARs, but does not change the total levels (including internalized surface receptors) of NR2B, which is observed in the neurons from APP Swe mice that over-express human APP with the familial Swedish mutation. And the effect of Aβ is completely inhibited by a γ-secretase inhibitor, which substantially reduces the Aβ level [30] . Consistent with these data, Aβ-mediated NMDAR endocytosis also occurs in other mouse cortical or hippocampal neurons that are exposed to Aβ [3, 13, [31] [32] [33] , and neurons or retinal membrane from transgenic animals with AD [13, 33, 34] .
Specifically, Aβ significantly reduces NR1 at synaptic sites, further supporting the selective action of Aβ on synaptic NMDARs [30] . In neurons from APP [V717I] transgenic mice, a model that mimics the early cognitive impairment in AD, the amounts of postsynaptic NR2B are also decreased [13] .
In addition, Li et al. used a biochemical approach to separate synaptic and extrasynaptic fractions from acute hippocampal slices after incubation with 7PA2 CM (medium from cells stably over-expressing a human APP mutation and secreting Aβ). They found a significant decrease of synaptic NR2B at 6 and 16 h, but no change of the NR2B levels in either the synaptic or extrasynaptic fractions at 30 min [35] .
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Although NMDARs can be redistributed from synaptic to extrasynaptic sites, Snyder et al. failed to find an increase in extrasynaptic staining of NMDARs after Aβ treatment [30] . Incubating neurons with Aβ does not change extrasynaptic NR2B clusters at 30 min, 6 h, and 16 h [35] , indicating that Aβ does not promote extrasynaptic NR2B
endocytosis.
Mechanistically, Aβ-mediated NMDAR endocytosis requires α-7 nicotinic acetylcholine receptors (α7nAChRs) and striatal-enriched protein tyrosine phosphatase (STEP) [30] .
Wang et al. reported that Aβ binding to neuronal
α7nAChRs promotes the aggregation of intraneuronal Aβ and the formation of neurofibrillary tangles (NFTs) [36, 37] .
S24795, a novel α7nAChR agonist, reduces the Aβ-α7nAChR interaction, decreases Aβ-induced NFTs and Aβ accumulation, and reverses the attenuation of Ca 2+ influx through NMDARs in the Aβ-infused mouse brain [38] . Similarly, a study on a transgenic mouse model of AD over-expressing APP and lacking the α7nAChR gene showed that these mice are better able to solve a cognitive challenge such as the Morris water maze test, and α7nAChR deletion protects the loss of synapses and preserves the capacity to elicit long-term potentiation (LTP) [39] . STEP61 levels are progressively increased in the prefrontal cortex of AD patients and transgenic mouse models of AD [33] . Using genetic manipulations to cognitive function, and facilitates LTP [40, 41] (Fig. 1 ).
Moderate ethanol consumption has been associated with a reduced risk of AD in several epidemiological studies. Recently, ethanol preconditioning-dependent neuroprotection was found to be associated with early enhancement of synaptic NR2B localization and NMDAR activity [42] . Also, chronic ethanol exposure increases synaptic NR2B clusters and synaptic NMDA currents, but does not change extrasynaptic NMDAR clusters [43] .
However, downregulation of NMDARs can also be neuroprotective. Pretreating cultured neurons with Aβ promotes NMDAR endocytosis, decreases Ca 2+ influx, and protects neurons from NMDA-and glutamate-induced excitotoxicity [31, 44] . Likewise, the retinas of transgenic mice over-expressing Aβ have reduced NR2B, and present with less NMDA-induced retinal damage than wild-type mice [34] .
Moreover, donepezil, an acetylcholinesterase inhibitor, decreases glutamate toxicity via promoting NMDAR endocytosis and attenuating glutamate-mediated Ca 2+ entry [45] .
Aβ Reduces Postsynaptic NMDA Currents
To investigate the effect of Aβ on synaptic transmission, excitatory postsynaptic currents (EPSCs) were recorded in neurons from mice over-expressing APP. Li et al. reported a signifi cant decrease of NMDA-EPSCs in slices treated with 7PA2 CM. Moreover, they suggested that an Aβ-mediated rise in glutamate levels leads to receptor desensitization and then causes NMDA-EPSC reduction [46] . Also, it has been reported that Aβ reduces NMDA postsynaptic currents [47] . A decrease in evoked-response amplitude could result from negative modulation of the presynaptic release machinery, yet Aβ does not alter the synaptic release probability and presynaptic vesicle release at presynaptic sites [2, 47, 48] . [1] . Pre-incubation of cortical and hippocampal neurons with a low (100 nmol/L) or a high concentration (1 μmol/L) .
Dysregulation of Extrasynaptic NMDARs Induced by Aβ
Aβ Enhances the Activation of Extrasynaptic NMDARs by Reducing Excitatory Amino-acid Transporters
The glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) are the main proteins responsible for removing excess glutamate from the synaptic cleft.
Considerable evidence supports the hypothesis that Aβ downregulates the uptake of glutamate by decreasing these glutamate transporters in both the cortex and fibroblasts of AD patients or animal models of AD [49] [50] [51] [52] , as well as astrocytes both in vitro and in vivo [53, 54] .
Recently, Bicca et al. revealed decreases in GLT-1
and GLAST expression and glutamate uptake in the hippocampus of Aβ-treated mice, which could be prevented by a selective and competitive NMDAR antagonist [10] .
Interestingly, disturbance of cholesterol metabolism or aging may contribute to a reduction in glutamate transporters [55, 56] .
Moreover, Aβ promotes extracellular glutamate release from hippocampal neurons [57] , and increases the hippocampal levels of extracellular glutamate [58] . After selectively blocking synaptic NMDARs, perfusing 7PA2 CM markedly increases NMDA-EPSCs, and a selective NR2B inhibitor strongly inhibits NMDA-EPSCs, suggesting that Aβ enhances the activation of extrasynaptic NR2B [35, 46] (Fig. 1) . Also, inhibition of glutamate transporters causes glutamate spillover from the synapse and increases extrasynaptic NMDA-EPSCs [35, 59] .
As discussed above, Aβ can decrease the NMDARmediated intracellular Ca 2+ concentration [13, 16, 31, 44] , but triggers a sustained Ca 2+ influx mediated by NMDARs [7, 15, 60] . This paradox may be explained by the activation of extrasynaptic NMDARs. Li et al. showed that the change in extrasynaptic NMDAR-mediated cytosolic Ca 2+ in response to NMDA is significantly greater in 7PA2 CM-treated neurons [35] , and this is significantly attenuated by memantine [7, 16, 60] , consistent with the notion that memantine predominantly blocks extrasynaptic NMDARs [21, 61, 62] .
Neurotoxicity Is Mediated by Extrasynaptic NR2B-NMDARs
NR2B-NMDARs are predominantly located at extrasynaptic sites in mature neurons, and their activation promotes cell death through a series of pathways, which have been described in detail elsewhere [63] . facilitates LTD through metabotropic glutamate receptors (300 pulses) or NMDARs (900 pulses). They found that the effect of Aβ is caused by the activation of extrasynaptic NR2B through the inhibition of glutamate uptake, as it can be prevented by an extracellular glutamate scavenger and is closely mimicked by the inhibition of glutamate uptake [46] . Likewise, Aβ-inhibited LTP shares the same mechanism [35, 64] .
Moreover, Aβ application impairs early neuronal function before major cytotoxic effects, including LTP, baseline synaptic transmission, spontaneous neuronal network activity, retraction of synaptic contacts, and accumulated Jacob (a messenger that couples extrasynaptic NMDAR activity to CREB) dephosphorylation in the nucleus; all these effects are blocked by extrasynaptic NR2B
antagonists [65] (Fig. 1) . Consistent with these reports, only NR2B antagonists, but not those of NR2A, protect against NMDA-induced excitotoxicity [16, 66] , Aβ-mediated inhibition of plasticity [67] , Aβ-induced PSD-95 and synaptophysin loss [5, 6] , and Aβ-increased Ca 2+ infl ux [16] , as well as Aβ-induced ROS production and endoplasmic reticulum stress [68] . In addition, activation of either synaptic or extrasynaptic NR2B results in excitotoxicity and neuronal apoptosis [66] .
The Balance between Synaptic and Extrasynaptic
NMDARs for Therapeutic Targeting
When glutamate is used to activate both extrasynaptic and synaptic NMDARs, the extrasynaptic receptors shut off synaptic NMDAR signaling [17, 18, 21, 23] . Conversely, enhancement of synaptic NMDAR activity protects against extrasynaptic NMDAR-induced neuronal death [69] . Thus, the selective enhancement of synaptic activity or reduction of extrasynaptic activity may be sufficient to prevent Aβ-induced neurotoxicity.
Aβ downregulates PSD-95 and synaptophysin in an NMDAR-dependent manner, and only extrasynaptic NR2B-NMDAR antagonists abrogate this effect, while blockade of synaptic NMDAR activity does not infl uence these effects [5, 6] .
However, pretreatment with a low dose of NMDA (1 μmol/L) prevents the actions of Aβ, and the protective effect is eliminated only by blockade of synaptic NMDARs. In contrast, a high dose of NMDA (10 μmol/L) potentiates the effect of Aβ, which is only abolished by ifenprodil [5] ,
suggesting that the enhancement of synaptic NMDAR activity can halt the manifestation of early-stage events in AD.
Memantine has received marketing authorization from the European Medicines Agency and the Food and Drug Administration (USA) for the treatment of moderate to severe AD. Recently, accumulating evidence indicates that memantine, at therapeutic concentrations, preferentially blocks extrasynaptic over synaptic NMDARs in hippocampal autapses and cortical neurons [21, 61, 62] . Blocking extrasynaptic NMDARs with memantine inhibits NMDARinduced KPI-APP expression and decreases Aβ expression and release both in cellular models and transgenic animals [19, 70] , reduces tau hyperphosphorylation [71, 72] and microtubule deregulation [12] , blocks excessive formation of ROS [7] and intracellular or mitochondrial Ca 2+ overload [7, 15, 60] , and prevents Aβ-inhibited LTP [73] and synaptic deterioration [3] .
In addition, memantine inhibits CREB shutoff and rescues neurons from NMDA-mediated toxicity [15, 23] .
Conclusions and Perspective
In summary, Aβ differentially affects the activity of synaptic Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic [18] NMDARs oppose synaptic NMDARs by triggering CREB
